Jul 29, 2025
Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe
Jun 24, 2025
Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects
Jun 23, 2025
Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy
Jun 18, 2025
Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth
Jun 16, 2025
Hoth Therapeutics to Attend 2025 BIO International Convention
Jun 12, 2025
Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases
Jun 11, 2025
Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities
Jun 05, 2025
Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities
Mar 31, 2025
Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage
Mar 26, 2025
Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation
Mar 18, 2025
Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment
Mar 05, 2025
Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting
Mar 04, 2025
Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease
Feb 10, 2025
Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic
Jan 08, 2025
Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries
Oct 29, 2024
Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study
Sep 05, 2024
Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial
Sep 05, 2024
Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001
Jul 16, 2024
Hoth Therapeutics Expands Clinical Trial for Cancer Patients
May 01, 2024
Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024